Company / Revenue
VYNE Therapeutics Inc. Revenue History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$501.0K
FY2025
5-year range
$424.0K / $21.0M
FY2021-FY2025
Trend
+18.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue returned to growth in FY2025 after 3 years of decline, reaching $501,000.
Based on SEC 10-K filings.
$501,000 in FY2025 with a 5-year CAGR of -32.6%.
Improved from $477,000 to $501,000 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -18.7%
- 5-Year CAGR
- -32.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -32.6%, indicating a declining trend.
- In FY2025, revenue increased 18.2% year-over-year.
- Peak revenue was recorded in FY2021.
- Lowest revenue in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $501.0K | +18.2% |
| FY2024 | $424.0K | -11.1% |
| FY2023 | $477.0K | -48.8% |
| FY2022 | $931.0K | -95.6% |
| FY2021 | $21.0M | +483.9% |
| FY2020 | $3.6M | - |
| FY2019 | $0 | - |
| FY2018 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026